Lothian NHS Board

Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Telephone: 0131 536 9000
www.nhslothian.scot.nhs.uk

Date: 16/11/2026
Our Ref: 12065
Enquiries to loth.freedomofinfomation@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Cancer treatment, July – September 2026, NHS Lothian Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	349
1.2 Apalutamide (Erleada)	7
1.3 Cabazitaxel	≤5
1.4 Darolutamide (Nubeqa)	21
1.5 Docetaxel	94
1.6 Enzalutamide (Xtandi)	237
1.7 Lutetium-177 PSMA-617 (Pluvicto)	0
1.8 Olaparib (Lynparza)	31
1.9 Relugolix (Orgovyx, Ryeqo)	0
1.10 Talazoparib (Talzenna)	0

Question:

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated for prostate cancer, July – September 2026, NHS Lothian	
Name of medicine	**Number patients treated**
2.1 Docetaxel for prostate cancer	19
2.2 Olaparib (Lynparza) for prostate cancer	≤5
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

Question:

3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated with first cycle or first dose, July-September 2026, NHS Lothian	
Name of medicine	**Number patients treated in Cycle 1 or Dose 1**
3.1 Abiraterone (Zytiga or generic abiraterone)	23
3.2 Apalutamide (Erleada)	≤5
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	≤5
3.4 Darolutamide (Nubeqa)	≤5
3.5 Enzalutamide (Xtandi)	23

Question:

4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Cancer treatment, July-September 2026, NHS Lothian		
Name of medicine	Total Number patients treated	Number patients received cycle 1 or dose 1
4.1 Darolutamide (Nubeqa) + Docetaxel	0	0
4.2 Darolutamide (Nubeqa) monotherapy	21	≤5
4.3 Olaparib (Lynparza) + Abiraterone	≤5	0

Question:

5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below.

Treatment switches, July – September 2026, NHS Lothian	
Name of medicine	Number patients switched
5.1 Abiraterone	0
5.2 Apalutamide	0
5.3 Enzalutamide	0

Question:

6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below.

Treatment for non-metastatic hormone sensitive prostate cancer, July – September 2026, NHS Lothian	
Name of medicine	Number patients treated
6.1 Abiraterone	127
6.2 Enzalutamide	0

Question:

7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026?

Answer:

The information you have requested is detailed in the table below.

Treatment with darolutamide, July – September 2026, NHS Lothian		
BlueTeq CDF code	**BlueTeq CDF description (copied from CDF List)**	**Number of patients**
DARO1	Darolutamide for non-metastatic hormone-resistant (castration-resistant) prostate cancer	9
DARO2	Darolutamide in combination with docetaxel and ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer	Info not available
DARO3	Darolutamide in combination with ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel	Info not available

Question:

8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below.

Treatment with Cemiplimab for non-small cell lung cancer, July – September 2026, NHS Lothian	
Product	**Number patients treated**
8.1 Cemiplimab (Libtayo) for Non-small Cell Lung Cancer	0

Question:

9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below.

Cemiplimab treatment for non-small cell lung cancer, July – September 2026, NHS Lothian Combination or monotherapy for Non-small Cell Lung Cancer	Number patients treated
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy	0
9.2 Cemiplimab monotherapy	0

Question:

10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Cancer treatment, July – September 2026, NHS Lothian Product	Number patients treated
10.1 Amivantamab (Rybrevant)	≤5
10.2 Lazertinib (Lazcluze)	≤5
10.3 Osimertinib (Tagrisso)	44

Question:

11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Cancer treatment, July – September 2026, NHS Lothian Product	Number patients treated
11.1 Amivantamab + Lazertinib	0
11.2 Amivantamab + Carboplatin + Pemetrexed	≤5
11.3 Amivantamab Monotherapy	0
11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy	0
11.5 Osimertinib Monotherapy	44

Question:

12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Treatment with Osimertinib, July – September 2026, NHS Lothian	
Product	**Number patients treated**
12.1 Osimertinib as adjuvant treatment	≤5

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at https://www.foi.scot/appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive